BioSpace News Archive

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the development of a novel anti-cancer cellular vaccine by reprogramming the unconventional suppressive mesenchymal stromal cells (MSCs) into potent antigen presenting cells (APCs).

Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, is pleased to announce the appointment of three new members to its Board of Directors.

Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), announced today that their Chief Executive Officer, Robert K. Brooks, JD, will participate in the Cell Therapy Durability Response Summit that will be held August 22-23, 2022.

Global AI drug discovery and development company Syntekabio will present its innovative and efficient proprietary AI-based drug discovery cloud platforms DeepMatcher® and NEO-ARS™, scheduled to launch this September, on Aug. 19 at the US-Korea Conference (UKC) in Arlington, Virginia.

The revenue generation opportunities in the bioremediation market are attributed to rapid industrial development across the world in recent years.

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced positive top-line Phase 3 results for garadacimab (CSL312), the company’s investigational first-in-class monoclonal antibody inhibiting Factor XIIa being developed as a long-term preventive treatment for patients with hereditary angioedema (HAE).

Wilmington, Delaware, United States, Transparency Market Research Inc. – Cell therapy, also known as cellular therapy or cytotherapy, is a type of biotherapy used to develop therapeutic strategies and drugs based on living cells

High Demand From Food And Beverage Industry Is Expected To Offer Lucrative Opportunities For Key Manufacturers During Forecast Period.

The Acute Respiratory Failures Segment Is Expected To Grow Impressively At A CAGR Of 11.4%